Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
ASNDNovo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
November 5, 2024
Read more →Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
ASNDAscendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments.
November 4, 2024
Read more →If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today
ASNDNovember 4, 2024
Read more →Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target
ASNDNovember 4, 2024
Read more →Ascendis Pharma, Novo Nordisk Partner For Development, Commercialization Of TransCon Technology-Based Products In Metabolic, Cardiovascular Diseases; Ascendis To Be Eligible To Receive Payments Of Up To $285M For Lead Program
ASNDNovember 4, 2024
Read more →$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
ASNDMay 17, 2024
Read more →Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Raises Price Target to $140
ASNDMay 16, 2024
Read more →Ascendis Presents Long-Term Data In Adult Patients With Hypoparathyroidism Treated With TransCon PTH through Week 110 In The PaTH Forward Trial Presented At ASBMR
ASNDSeptember 12, 2022
Read more →